title: Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
abstract: OBJECTIVE
  To evaluate the incidence of venous thromboembolism (VTE) in ambulatory pancreas cancer patients receiving chemotherapy and analyze Khorana's predictive model of chemotherapy-associated thrombosis.
  
  
  METHODS
  We performed a retrospective review to determine the incidence of VTE in the gastrointestinal cancer unit of our center. Between 2008 and 2011, 84 consecutives patients diagnosed with pancreas adenocarcinoma were identified and included in the analysis. Pancreatic neuroendocrine tumors were excluded.
  
  
  RESULTS
  Thirty patients experienced VTE (35.7 %) and 66 % of the events were diagnosed during the first 6 months after diagnosis. Khorana's score: 33.3 % of the intermediate category patients developed a venous thromboembolic event and 37.5 % in the high-risk category.
  
  
  CONCLUSIONS
  The high incidence of VTE observed in this study is consistent with prior reports. Specific predictive model for chemotherapy-associated thrombosis in pancreatic cancer must be investigated.
authors.affiliation: Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain, andresmunmar@hotmail.com.
authors.forename: A J
authors.initials: AJ
authors.lastname: Muñoz Martín
authors.forename: P
authors.initials: P
authors.lastname: García Alfonso
authors.forename: A B
authors.initials: AB
authors.lastname: Rupérez Blanco
authors.forename: S
authors.initials: S
authors.lastname: Pérez Ramírez
authors.forename: M
authors.initials: M
authors.lastname: Blanco Codesido
authors.forename: M
authors.initials: M
authors.lastname: Martín Jiménez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000453:epidemiology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D017671:Platinum Compounds / Q000008:administration & dosage; D011655:Pulmonary Embolism / Q000453:epidemiology*; D012189:Retrospective Studies; D018570:Risk Assessment; D054556:Venous Thromboembolism / Q000453:epidemiology*; D020246:Venous Thrombosis / Q000453:epidemiology*; D000093542:Gemcitabine
chemical_list: D017671:Platinum Compounds; D003841:Deoxycytidine; D005472:Fluorouracil; D000093542:Gemcitabine